Eli Lilly Surges On 'Assertive' Guidance That Assuages Novo Nordisk-Tied Worries

Core Viewpoint - Eli Lilly's stock experienced a significant surge following the company's impressive fourth-quarter earnings report, which exceeded analyst expectations substantially [1]. Financial Performance - Eli Lilly reported adjusted earnings of $7.54 per share, surpassing the FactSet analyst consensus of $6.91 per share [1]. - The company achieved fourth-quarter sales of $19.29 billion, significantly higher than the expected $17.94 billion [1]. - In comparison to the previous year, Eli Lilly's earnings per share increased from $5.32, and sales rose from $13.53 billion [1]. Product Impact - The strong performance was largely driven by the success of the diabetes drug Mounjaro, which has contributed to the company's robust earnings and positive guidance for the future [1].